Validated High-performance Liquid Chromatographic Method Research Articles

Validation of High-Performance Liquid Chromatography method for the determination of doxorubicin in proliposomal drug delivery system formulation

The objective of this study develop a novel proliposome formulation containing Doxorubicin (Dox) and was to validate sensitive and selective reversed-phase high-performance liquid chromatographic (HPLC) method for the evaluation of Dox concentrations of proliposome formulation. The samples were chromatographed on C18 column (Zorbax Eclipse Plus 5µm 4.6 x 250 mm) using a mobile phase with Sodium Lauryl Sulphate solution:Acetonitrile (%50:%50) and detected 254 nm. Linearity was confirmed in the concentration range 10.0–75.0 µg/mL. Specificity, linearity, working range, LOD, LOQ, accuracy, precision, robustness and system suitability studies were done from HPLC validation parameters. Liposome formulation containing Dox was developed by pH gradient method then proliposome formulation was developed with lyophilisation technique. The developed HPLC method, the encapsulation capacity (EE%) was found to be 90%±0.5 and the drug loading capacity (DL%) was found to be 100.0%±0.3. In addition, in vitro release studies and stability study results were evaluated with validated HPLC method. It was observed that developed Dox-proliposome formulation increased Dox release at pH 5.5, pH 6.5 and pH 7.5 by 23.9%, 30.2% and 14.8%, respectively, compared to commercial product. The result of F2 test performed in pH 7.5 media was 51.4%. According to the results of the physicochemical tests performed within the stability studies, it was observed that there was no significant change at the end of 12 months. These results show that the HPLC method developed, and validation study performed are important and applicable in the development, characterization, in vitro release and stability studies of the novel proliposome formulation.

Potential application of a chromatographic method in the accurate simultaneous determination of amikacin sulfate and its preservation additives in different pharmaceutical dosage forms

Aminoglycosides are antibiotics with high clinical importance that face a great challenge of detection in the UV range. This study aimed to develop an accurate, simple, and sensitive validated high-performance liquid chromatographic (HPLC) method for the determination of amikacin sulfate, one of the widely used aminoglycoside antibiotics in the pharmaceutical formulations, as the target analyte without interference from its preservation additive sodium metabisulfite in the pharmaceutical dosage forms without the usage of any derivatization reactions. The developed method is based on direct UV detection at 205 nm using a gradient mobile phase consisting of acetonitrile as an organic solvent and buffered solution; pH 3.0. This method was developed on a reversed-phase ZORBAX ECLIPSE XDB-C8 (4.6 × 250 mm, 5-μm) analytical column with a flow rate of 1.5 mL min−1 at a column temperature of 35 °C. The separation of amikacin sulfate and sodium metabisulfite was achieved at 3.7, and 1.5 min, respectively. The developed method validation was performed as prescribed by the International Conference on Harmonization (ICH) guidelines to confirm its linearity, precision, and accuracy. Finally, using simple, commonly available analytical tools, safe buffer concentration on the HPLC system, and without any complicated equipment or challenging derivatization steps, our validated HPLC method was applied for the simultaneous determination of amikacin and sodium metabisulfite in commercially available pharmaceutical formulations in a single method of analysis.

Inhibitory Effects on Clinical Isolated Bacteria and Simultaneous HPLC Quantitative Analysis of Flavone Contents in Extracts from Oroxylum indicum

Oroxylum indicum is a medicinal plant in Thailand, which has been used as a tonic and for the treatment of various diseases. Extracts from various parts of O. indicum were reported as promoting in vitro antioxidant and antibacterial effects. Phytochemical analysis suggested that this plant contained some flavones. O. indicum fruit and seed water and ethanol extracts and their major flavonoids including baicalein, baicalin, and chrysin were tested for in vitro antibacterial activities on four clinical isolated bacteria, namely, Staphylococcus intermedius, Streptococcus suis, Pseudomonas aeruginosa, and β-Escherichia coli, using a broth micro-dilution assay. The amounts of these three major flavonoids were also quantitatively analyzed using the high-performance liquid chromatographic (HPLC) method. O. indicum fruit ethanol extract from Nakhon Pathom province (OFNE) promoted the strongest antimicrobial activity against four clinical pathogenic bacteria, including S. intermedius (IC50 = 1.30 mg/mL), S. suis (13.59% inhibition at 7.81 mg/mL), P. aeruginosa (IC50 = 39.20 mg/mL), and β-E. coli (IC50 = 66.85 mg/mL). Baicalin showed high in vitro antibacterial effect to all tested bacteria. From the optimized and validated HPLC method, baicalin, baicalein, and chrysin contents in O. indicum extracts were 0.19 ± 0.00 − 9.45 ± 0.13, 0.14 ± 0.00 − 1.27 ± 0.02, and 0.02 ± 0.00 − 0.96 ± 0.02 g/100 g extract, respectively. Baicalin was found to be the major compound in O. indicum seed extract followed by baicalein, whereas chrysin was found in lower amounts than the amounts of the other two flavonoids in all O. indicum extracts.

Potential in vitro anti-allergic, anti-inflammatory and cytotoxic activities of ethanolic extract of Baliospermum montanum root, its major components and a validated HPLC method

BackgroundThe root of Baliospermum montanum has been used as an ingredient of traditional Thai medicines for the treatments of several diseases including itching eczema, muscle and joint inflammation, and cancer. Few studies have been done on phytochemical components of this root. In this study, we isolated major compounds of the crude ethanolic extract of B. montanum root and developed and validated a high performance liquid chromatographic (HPLC) method for the determination of its major components. We then investigated anti-allergic, anti-inflammatory and cytotoxic activities of the extract.MethodsThe aims of this study were to investigate in vitro activities including inhibitory effect of β-hexosaminidase released from RBL-2H3 cells, inhibition of nitric oxide (NO) production from RAW 264.7 cells and cytotoxic activity against cancerous liver cell lines (HepG2 and KKU M156) by using sulforhodamine B (SRB) assay. Isolation of major components was conducted by using column chromatographic method. Isolated major compounds were analyzed by using high performance liquid chromatography (HPLC).ResultsThe crude extract exhibited the highest cytotoxic activity, with IC50 less than 1 μg/mL, while its anti-allergy and anti-inflammation were also potent with IC50 less than 6 μg/mL. Three propiophenones isolated from B. montanum root exhibited moderate cytotoxic activities (IC50 > 20 μg/mL). Two of the propiophenones found were major components that can be detected by HPLC. The developed and validated HPLC method showed good accuracy, precision, and linearity.ConclusionThe results of this study suggested that ethanolic extract of of B.montanum root can be a potential source of anti-allergy, anti-inflammation, and anti-cancer compounds. The isolated compounds can serve as markers when B. montanum is used in herbal remedies but not as overall responsive markers. The HPLC method developed may be useful for quality control in the production of the extract and for further formulation developments. However, investigation of several associated biological activities is necessary before the development can proceed further. Minor active compounds should be isolated and a more sensitive analytical method should be developed to detail the key responsive components of the ethanolic extract of B. montanum root.

A new validated high-performance liquid chromatography method for standardization of rosmarinic acid in Salvia extracts

Introduction: Tea bags or infuses of Salvia species from Lamiaceae family are traditionally used for the treatment of cough, and throat inflammations. They are known for antioxidant properties mainly related to the presence of rosmarinic acid (RA). Therefore it is necessary to develop a reliable analytical method for RA assay for standardization of Salvia species and also other plants containing RA like Melissa, Origanum, Lavandula, Rosmarinus, Thymus, Zataria, Mentha, Perovskia, Zhumeria, and Satureja species. In this study using a suitable extraction method by removing unwanted components present in crude methanol extract, phenolic content containing RA was extracted from dry powders of six Salvia species. Then, a suitable high-performance liquid chromatographic (HPLC) method was optimized for quantification of RA in Salvia species. Methods: HPLC analysis was done on a Waters system, equipped with 515 HPLC pump and waters 2487 dual wavelength absorbance detector. The column was a Nova-Pak C18 (3.9 × 150 mm), and Millenium software was used for the determination of the compounds and processing the data. The method was validated according to USP 32 requirements. Results: Among the investigated 6 species, S. virgata was the richest in RA level, demonstrating 3.50 ± 0.12 mg/g, followed by S. sclarea and S. chloroleuca showing 1.65 ± 0.08 and 1.65 ± 0.21 mg/g. S. ceratophylla with 0.10 ± 0.01 mg/g of RA in dried plant powder was the poorest. Conclusion: The validated HPLC method allows determination of amounts as low as 2.5 µg/ mL of RA and linearity in the ranges of 2.5-25 µg/mL and 100–600 µg/mL, which is suitable for standardization of Salvia species in traditional and pharmaceutical formulations

Rapid determination of oxindole alkaloids in cat's claw by HPLC using ionic liquid-based microwave-assisted extraction and silica monolithic column.

Cat's claw is a large woody vine with hook-like thorns, and has been traditionally used to treat inflammatory disorders in South and Central America. In this study, a rapid, validated high-performance liquid chromatographic (HPLC) method using a silica monolithic column was developed for the simultaneous determination of oxindole alkaloids, namely rhynchophylline, pteropodine, isomitraphylline and isopteropodine, in cat's claw. The ionic liquid-based microwave-assisted extraction (ILMAE), considered as an environmentally friendly and powerful tool, was first applied in the extraction of oxindole alkaloids. To optimize the HPLC method, the stationary phases, pH values of mobile phase and flow rates were investigated. The validated HPLC method using a Monolithic RP18e column (100 × 4.6 mm) enables these analytes to be separated almost twice as fast as with a conventional particulate column (~16 vs ~30 min) with limits of quantification and detection of 0.5 and 0.15 μg/mL, respectively. The ILMAE conditions were optimized by the Taguchi orthogonal array design. In comparison with conventional water boiling extraction, ILMAE offers almost four times higher yields within an extremely short extraction time. The developed HPLC coupled with ILMAE method could be efficient and practical for rapid determination of oxindole alkaloids in cat's claw.

Development and validation of a high performance liquid chromatography method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor and its application to a pharmacokinetic study in rats.

A sensitive and selective high-performance liquid chromatographic (HPLC) method for determination of 6-benzyl-1-benzyloxymethyl-5-iodouracil (W-1), a novel non-nucleoside reverse transcriptase inhibitor in rat plasma, was developed and validated. Chromatographic separation of W-1 and megestrol acetate (internal standard) was achieved on a reversed-phase C18 column at 25°C. The mobile phase was consisted of acetonitrile-water (60:40, v/v) and pumped at a flow rate of 1.0 mL/min. The ultraviolet (UV) detector was set at the absorption wavelength of 284 nm. The calibration curve for W-1 was linear over the concentration range of 0.01-8 µg/mL and the lower limit of quantification was 10 ng/mL. The intra- and inter-day precision and accuracy were <8.9 and 5.3%, respectively. The extraction recoveries ranged from 97.9 to 101.6%. The validated HPLC method was successfully applied to a pharmacokinetic study of W-1 in rats.

Development of a Validated HPLC Method for the Simultaneous Determination of Anabolic Steroids in Biological Fluids

A reversed phase high performance liquid chromatographic (HPLC) method is developed and validated for the simultaneous determination of anabolic steroids: testosterone (TES), epitestosterone (EPI), and nandrolone (NAN). The analytical column, Inertsil C8, 5 µm, 250 × 4 mm, was operated at ambient temperature. Isocratic elution was performed using a mixture of 50% buffer solution CH3COOH 0.11% –CH3COONa 7.5 mmol/L, pH = 4, 45% CH3CN and 5% CH3OH, at a flow rate of 1.1 mL/min. UV detection was performed at 238 nm. The detection limits of the method were 2.4 ng for NAN, 3.6 ng for TES, and 2.6 ng for EPI in blood plasma, and 2.7 ng for NAN, 1.1 ng for TES, and 3.8 ng for EPI in urine, per 20 µL injection volume. Alprazolam was used as internal standard at a concentration of 2 ng/µL. Validation of the method was performed in terms of accuracy and precision: intra-day assay (n = 6) and inter-day assay (n = 3 × 6) and was found to be satisfactory, with high accuracy and precision results. Sample preparation involved solid phase extraction on Nexus cartridges with high recoveries. The developed method was successfully applied to the analysis of urine samples of one female and 9 male volunteers.

Determination of CH330331, a novel 4-anilinoquinazoline inhibitor of epidermal growth factor receptor tyrosine kinase, in human Caco-2 monolayers by high performance liquid chromatography with ultraviolet detection: Application to a trans-epithelial transport study

4-Anilinoquinazolines (e.g. Iressa and Glivec) are a class of epidermal growth factor receptor tyrosine kinase (EGFR-TK) inhibitors widely used to treat non-small cell lung cancer and other tumors. However, low clinical response rate, resistance, and host toxicity of currently available EGFR-TK inhibitors prompt the development of second generation of TK inhibitors with improved efficacy, selectivity, and less resistance. CH330331 is a recently synthesized novel 4-anilinoquinazoline analog with confirmed anticancer activity in vitro and in vivo. To predict its oral pharmacokinetic behavior and transport nature in the intestine before entering clinical trials, we have developed and validated a high performance liquid chromatographic (HPLC) method for the determination of CH330331 in Caco-2 (a human colon cancer cell line) monolayers. The developed HPLC method was sensitive and reliable, with acceptable accuracy (90–110% of nominal values) and precision (intra- and inter-assay R.S.D. < 10%). The total running time was within 10 min, with acceptable separation of the target analytes. The lower limit of quantitation (LLOQ) value for CH330331 was 200 ng/ml when an aliquot of 100 μl sample was injected onto the HPLC. The validated HPLC method was applied to characterize the epithelial transport of CH330331 in Caco-2 monolayers. The transport of CH330331 across the Caco-2 monolayers from the apical to basolateral side was 8- to 10-fold higher than that from the basolateral to apical side. Co-incubation of sodium azide or MK-571, but not verapamil, significantly inhibited the apical to basolateral transport of CH330331. These findings provide initial evidence that the intestinal absorption of CH330331 is mediated by an active mechanism. Further studies are required to explore the interaction of CH330331 with ATP-binding cassette transporters and the possible influence on its pharmacokinetics and pharmacodynamics.

Bioequivalence assessment of the two brands of glimepiride tablets

Glimepiride, as an antidiabetic from the group of sulfonylurea, is administered perorally in the treatment of diabetes mellitus. The aim of this study was to compare pharmacokinetic profiles and relative bioavailabilities of the two oral formulations of glimepiride, generic and innovator tablets, after a single dose of the active drug. An oral dose of 6 mg glimepiride was given under fasting conditions to 24 healthy volunteers. A one-week washout period was applied between the two consecutive periods. The serum samples obtained before dosing, and at various time points up to 48 hours, were analyzed for glimepiride concentration using the validated high-performance liquid chromatographic method with ultraviolet detection. Pharmacokinetic parameters representing early (maximal concentration, time to reach maximal concentration) and total exposure (area under the curve from the time 0 to the infinite time) to glimepiride were obtained and further analyzed using the multifactorial analysis of variance and the non-parametric Wilcoxon signed ranks test. Comparison of the secondary kinetic variables was only descriptive. The point estimates of the ratios of geometric means (test/reference) of maximal concentrations and areas under the curve were 1.046 (90% confidence interval: 0.906-1.208) and 1.022 (90% confidence interval: 0.856-1.220), respectively, while the median values of times to reach maximal concentration, at 5% level of significance, did not differ significantly. Both formulations were well tolerated. Transient mild hypoglycaemia, which had been noted in 6 participants, resolved spontaneously within 30-60 minutes. Since all the parametric 90% confidence intervals for the log-transformed main variables of glimepiride were within the 0.80 and 1.25 interval, accepted as the definition of bioequivalence, and the differences in times to reach maximal concentration also did not reach statistical significance, studied tablets were considered bioequivalent.

A validated HPLC method for the assay of xanthone and 3-methoxyxanthone in PLGA nanocapsules.

This work relates the development and validation of a simple reversed-phase high-performance liquid chromatographic (HPLC) method for the analysis of xanthone (XAN) and 3-methoxyxanthone (3-MeOXAN) in poly(D,L-lactide-co-glycolide) (PLGA) nanocapsule formulations. This method does not require any complex sample extraction procedure. Chromatographic separation is made with a reversed-phase C(18) column, using methanol-water (90:10, v/v) as a mobile phase at a flow rate of 1 mL/min. Identification is made by UV detection at 237 nm. The isocratic system operates at ambient temperature and requires 7 min of chromatographic time. The developed method is statistically validated according to United States Pharmacopoeia 25 and International Conference on Harmonization guidelines for its specificity, linearity, accuracy, and precision. The assay method proposed in this study is specific for XAN and 3-MeOXAN in the presence of nanocapsule excipients. Diode-array analyses confirm the homogeneity of XAN and 3-MeOXAN peaks in stressed conditions. Standard curves are linear (r > 0.999) over the concentration range of 0.4-2.5 and 1.0-5.8 micro g/mL for XAN and 3-MeOXAN, respectively. Recovery from nanocapsules ranges from 99.6% to 102.8% for XAN and 98.8% to 102.4% for 3-MeOXAN. Repeatability (intra-assay precision) is acceptable with relative standard deviation values of 1.2% for XAN and 0.3% for 3-MeOXAN.

A Validated HPLC Method For the Determination of Carbamazepine and Carbamazepine 10,11-Epoxide in Human Plasma

Abstract A validated reversed-phase high-performance liquid chromatographic (HPLC) procedure employing ultra-violet (UV) detection for the analysis of carbamazepine (Tegretol®, CBZ) and its predominant metabolite, carbam-zepine 10, 11-epoxide (CBZ-E), in human plasma is reported. The method is rapid and coupled with standard HPLC procedures leads to a sensitive, accurate, and reproducible assay. The retention times of CBZ-E, CBZ, and internal standard, are 3.3, 7.0 and 10.8 minutes, respectively, with an overall chromatographic run time of 12.0 minutes. The peak height ratio versus plasma concentration is linear over the range of 0.10 to 10.0 μg/mL for each analyte and exhibits correlation coefficients of 0.9968 or better (n=7). The mean absolute recoveries of CBZ and CBZ-E using the described assay are 89.8 and 86.8%, respectively. The inter- and intra-day accuracy and precision is within 11.6% of the actual values for all concentrations investigated. Furthermore, the assay is suitable for obtaining the AUC, Cmax and tfrac12 of CBZ and CBZ-E in human plasma after a single 400 mg oral dose of Tegretol®.